Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PPPurple Biotech Ltd. logo

Purple Biotech Ltd. (PPBT)

NASDAQ Capital Market · Currency in USD
$1.08 ▲ +0.03 (+2.86%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.01 ▼ -0.07 (-6.62%)
After hours: Oct 23, 6:44 PM ET

Summary

Previous Close
$1.05
Open
$1.09
Day's Range
$1.02 – $1.09
52 Week Range
$1.02 – $14.10
Volume
23,281
Avg. Volume
1,044,201
Market Cap
$149.13K
Beta (5Y Monthly)
-0.55
PE Ratio (TTM)
--
EPS (TTM)
-$2.26
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Purple Biotech Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
10
CEO
Gil Efron

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$2.88
DateEst.Actual
Aug 7, 2026-$0.98$1.07Beat
May 15, 2026-$3.80-$0.09Beat
Mar 13, 2026-$3.40-$19.85Miss
Nov 14, 2025-$2.60-$2.90Miss
Aug 6, 2025-$2.10-$4.00Miss
May 21, 2025–-$1.70

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PPBT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.